JDRF Invests in TetraGenetics’ Innovative Approach to Type 1 Diabetes Prevention
A unique scientific approach to preventing, treating and, perhaps one day, curing type 1 diabetes is being coupled with JDRF’s equally innovative approach to funding such studies in a new partnership that might move the promise of a preventive therapy and improved treatment for the condition closer to reality.
“This is a very targeted therapeutic approach to addressing type 1 diabetes,” says Dr. Ted Clark, the Chief Scientific Officer for TetraGenetics, a company that has been working for the past several years on developing drugs to prevent and treat diabetes. “Our technology has the potential to effectively block the specific autoimmunity response that is responsible for causing the disease.”
JDRF believes in TetraGenetics’ innovations to the point they are putting their money and support behind the company and its approach to addressing a potential type 1 diabetes preventive therapy. It announced that one of the organization’s first investments from their new T1D Fund—a fund that specifically supports “high-impact early-stage investments to accelerate commercial development of life-changing therapies for people living with T1D”—will be made in TetraGenetics.
“We think the work they are doing could have a real impact,” says Dr. Jonathan Behr, the Managing Director of the T1D Fund. “Our belief is that this is a partnership that could show real results and change lives for the better.”
To fully understand the mechanizations of TetraGenetics’ technology and how it applies to type 1 diabetics you need to lean back to take a macro view of what c Continue reading